Exscientia PLC
NASDAQ:EXAI
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Exscientia PLC
Stock-Based Compensation
Exscientia PLC
Stock-Based Compensation Peer Comparison
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exscientia PLC
NASDAQ:EXAI
|
Stock-Based Compensation
ÂŁ31m
|
CAGR 3-Years
122%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Stock-Based Compensation
$11.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Stock-Based Compensation
$32.7m
|
CAGR 3-Years
59%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Stock-Based Compensation
ÂŁ32.5m
|
CAGR 3-Years
58%
|
CAGR 5-Years
117%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Exscientia PLC's Stock-Based Compensation?
Stock-Based Compensation
31m
GBP
Based on the financial report for Dec 31, 2023, Exscientia PLC's Stock-Based Compensation amounts to 31m GBP.
What is Exscientia PLC's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
122%
Over the last year, the Stock-Based Compensation growth was -16%. The average annual Stock-Based Compensation growth rates for Exscientia PLC have been 122% over the past three years .